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Coronary artery disease is a major cause of morbidity and mortality in the Western countries. Acute 
myocardial infarction is a serious and often lethal consequence of coronary artery disease, resulting in 
contractile dysfunction and cell death. It is well known that unbalanced and high steady state levels of 
reactive oxygen and nitrogen species (ROS/RNS) are responsible of cytotoxicity, which in heart leads to 
contractile dysfunction and cell death. Pre- and post-conditioning of the myocardium are two treatment 
strategies that reduce contractile dysfunction and the amount of cell death considerably. Paradoxically, 
ROS and RNS have been identified as a part of cardioprotective signaling molecules, which are essential in 
pre- and post-conditioning processes. S-nitrosylation of proteins is a specific posttranslational 
modification that plays an important role in cardioprotection, especially within mitochondria. In fact, 
mitochondria are of paramount importance in either promoting or limiting ROS/RNS generation and 
reperfusion injury, and in triggering kinase activation by ROS/RNS-signaling in cardioprotection. These 
organelles are also the targets of acidosis, which prevent mitochondrial transition pore opening, thus 
avoiding ROS induced ROS release. Therefore we will consider mitochondria as either targets of damage 
or protection from it. The origin of ROS/RNS and the cardioprotective signaling pathways involved in 
ROS/RNS-based pre- and post-conditioning will be explored in this article. A particular emphasis will be 
given to new aspects concerning the processes of S-nitrosylation in the cardioprotective scenario.  
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Introduction 
Although high levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS) induce 
structural modifications of the proteins, lipids and genes that impact on cell function and death, ROS/RNS 
can activate signaling pathways that contribute to ischemic preconditioning (IP) and postconditioning 
(PostC). IP and PostC are two cardioprotective strategies able to protect the heart from 
ischemia/reperfusion (I/R) injury [140, 151, 240] via activation of physiological mechanisms, which 
comprise ROS and RNS production by several processes, including mitochondrial enzyme 
activation/inactivation [45, 57, 81, 124, 160, 161, 167, 219]. It is well known that in these two 
cardioprotective strategies a pivotal role is also played by the gradual normalization of intracellular pH in 
the initial phase of reperfusion [45, 97, 165]. We will see that this favors redox signaling and the 
activation of a complex cascade of signal molecules. Moreover a role of paramount importance is played 
by the prevention of the opening of the so-called mitochondrial permeability transition pore (mPTP) in 
post-ischemic phase in which also acidosis and redox signaling play pivotal roles [43, 44, 97]. 
Myocardial cell death due to I/R is a major cause of morbidity and mortality in the Western world. In the 
past few decades, it has become clear from experimental studies that the myocardial damage due to I/R 
can be reduced. This has motivated intense study of the mechanisms of cardioprotection. An initial 
impulse to the concept of cardioprotection was given by the seminal studies of Braunwald and colleagues 
in the early seventies [130, 131]. The finding that the infarct size was related to ischemic time led to the 
corollary that the infarct size could be limited by initiating reperfusion as early as possible (from those 
studies we now say: “Time is muscle”). This point of view paved the way to revascularization by 
thrombolysis, angioplasty, stenting and coronary artery bypass grafting surgery. Therefore, there was a 
scientific rationale to develop therapies to reduce the infarct size. These therapies were aimed at 
attenuating the recognized contributors to acute ischemic injury. Studies became focused on 
pharmacological treatments during or after ischemia. Many of these approaches failed in clinical trials. In 
particular, therapies with antioxidants failed in patients with cardiovascular diseases, despite the fact 
that many of these diseases including atherosclerosis, heart failure, and myocardial infarction appear to 
be related to altered redox regulation and increased oxidative stress [129]. The question then arises: why 
did these antioxidants studies fail? The answer to this question is not easy, as the reader can understand 
from the detailed discussion on this topic given elsewhere [206, 213, 215]. First of all, we must consider 
that a substantial lack of efficacy on cardiovascular morbidity and mortality has been demonstrated for 
different doses of “traditional” antioxidants, in diverse population groups and in different clinical trials 
[227]. This meta-analysis [227] clearly suggests that we need more hypothesis-driven clinical-trial 
designs. These should be guided by a rigorous and deeper understanding of the complex pathophysiology 
of ROS/RNS. Moreover, future research should develop newer antioxidant compounds, more specific, 
with a more favorable pharmacodynamic profile and/or impacting oxidative stress through different 
mechanisms. Yet, one fundamental issue is: what population is likely to benefit from antioxidant 
supplementation? The majority of the studies, so far, enrolled patients at high risk, characterized by 
established atherosclerotic damage, which is unlikely to recovery with antioxidant treatment. Besides 
populations under study, the role of other trial-design issues, such as duration of treatment, outcomes 
measured and concomitant therapy should not be underestimated. The failure of “traditional” 
antioxidants may also be partially explained by the difficulty to delivery these drugs to the sites of ROS 
generation at the right moment and in sufficient amount to quench oxidative stress [10, 75] and by the 
fact that chemical reactions between ROS, RNS and their targets may be faster than those with 
exogenous antioxidants [213]. Moreover, among the reasons of the failure of antioxidants, we can also 
suggest the fact that in the past their administration was based on the concept that ROS/RNS only have 
deleterious effects. Instead, as we know, some ROS/RNS play a role as intracellular mediators in 
physiological processes such as vasodilatation, cell growth and angiogenesis. Collectively, these 
considerations may provide an explanation to the failure of “traditional” antioxidants. Thus, rather than 
discarding the oxidative stress hypothesis, evidence suggests that we need more rigorous understanding 
of the complex physiology of ROS/RNS and of the multifaceted pharmacology of antioxidants. As we will 
further discuss, an important role of ROS/RNS has also been shown in protective mechanisms against I/R 
injury, such as pre- and post-conditioning. Thus, in certain settings, ROS/RNS quenching might have 
deleterious implications that offset the impact on organ function. In other words, the concept of redox 
balance implies that the reactive species are also important determinants of the normal cellular function, 
signal transduction underlying epigenetic- and genetic-regulation, and determination of cellular 
phenotype, even in I/R scenario. Clearly interference with this physiological redox signaling leads to 
compromised cell function. Therefore, cellular function requires an optimal redox environment and 
alterations in redox potential have major cellular consequences. Importantly, the redox conditions of the 
cell may be considered a continuum that range from reductive to oxidative stresses, in which the 
biological extremes of the redox spectrum play pivotal roles in disease pathogenesis. The notion that 
reductive stress predisposes to cardiomyopathy as much as oxidative stress is gaining ground among 
biologists. Due to space constrain we cannot consider the reductive stress issue here but the reader is 
kindly redirect to a recent review on this topic [27]. 
There is no doubt that I/R perturbs the redox balance towards redox stress; however a simple use of a 
general antioxidant may not be the solution. In fact, as discussed above, several trials failed when 
antioxidants were used to limit injury due to ischemic coronary artery disease. Therefore, we think that it 
is mandatory to better understand the pathophysiology of redox activity in each pathological condition 
before we try to propose any specific antioxidant therapeutic strategy. This is especially true for 
cardioprotection against I/R injury in which a delicate beneficial-to-deleterious switch seems to be 
present. A better understanding of the complex regulatory systems, particularly in human hearts, is 
necessary to progress with this approach [86]. 
In the present review we bring readers up to date on biologically useful concepts in a constantly changing 
field. In particular, we will consider: 1) the novel viewpoint of redox balance as a variable continuum, in 
which chemistry and signaling role of redox species may vary depending on biological conditions (e.g. 
normal-perfusion, ischemia, reperfusion etc), 2) the importance of redox signaling (oxidative and 
nitrosative signaling) in the physiological regulation of many processes, 3) the concept that a reactive 
species is not always deleterious and 4) the new concept that reactive species may be beneficial even in 
reperfusion.  
Clearly, from 1986, when the IP phenomenon was described by Murry, Jennings and Reimer [140], the 
research in the field increased exponentially. In this seminal study the authors reported that 4 cycles of 5-
min ischemia/5-min reperfusion prior to a 40-min coronary occlusion decreased infarct size by 75% 
compared to the control dogs with 40-min of coronary occlusion only. Then in 2003 another big impulse 
to research was given by the most improbable observation that the intermittent interruption of coronary 
flow in the very early phase of a reperfusion leads to cardioprotection [240]. Vinten-Johansen’s group in 
such a study suggested that PostC protocol obtained with 30-s of reperfusion followed by 30-s of 
coronary occlusion repeated for three cycles at the very onset of reperfusion is as cardioprotective as 
preconditioning. It soon became clear that in these two cardioprotective strategies the redox signaling 
plays a role of vital importance. These strategies to protect the heart trigger protective pathways that 
modify cell membrane, cytosol and organelle composition and function. In particular, both pre- and post-
conditioning include triggers, mediators and effectors converging on mitochondria, which are involved in 
many phases of the protective process. Here we explore particular aspects of these two strategies and 
especially those related with redox stress and redox signaling. In this context the role of S-nitrosylation of 
critical proteins, especially within mitochondria is rapidly gaining ground. 
Ischemic preconditioning, a brief synopsis  
Ischemic preconditioning has become the ‘gold standard’ treatment by which other therapies are judged; 
it consists of a series of brief periods of I/R performed before the infarcting ischemia (mechanical 
preconditioning), and has shown that infarct size can be modified by triggering endogenous mechanisms 
of protection. Preconditioning not only reduces infarct size, but also apoptosis, endothelial dysfunction 
and activation as well as neutrophil adhesion and inflammatory response. It also reduces stunning (the 
contractile depression which follows ischemia) and arrhythmias [21, 52, 149] (Figure 1). 
It has been shown that preconditioning can also be induced by pharmacological treatments and a similar 
protection can be induced by exercise protocols [49]. Moreover preconditioning, improving endothelial 
function also ameliorates vascular responsiveness to endothelial-dependent vasodilatation. Finally, it has 
been shown that IP can slow mitochondrial metabolism [33, 49, 67, 150, 152, 157, 162].  
When considering preconditioning it is useful to think in terms of triggers, memory, mediators and end-
effectors. The current theory of IP protection considers a trigger phase in which agonists of surface 
receptor couple through multiple pathways to protein kinase C (PKC) activation via an important 
contribute of mitochondrial ROS/RNS signaling. There is an ischemic phase in which PKC and perhaps 
other kinases act as a memory, and there is a reperfusion phase in which the mediators and end-effectors 
are recruited [43]. Among mediators and end-effectors of protection the recruitment of protective 
pathways and prevention of the opening of mPTP play a role of paramount importance [98]. 
In the trigger phase, during the brief preconditioning periods of I/R, membrane receptor 
population occurs (i.e., ligands are formed/released and in autocrine/paracrine fashion will target 
their receptors). This will lead, via a complex mechanism (see below), to the opening of 
mitochondrial ATP-sensible K+ channels (mKATP) and consequently to mitochondrial ROS/RNS 
formation [155] ROS/RNS, together with a diacylglycerol (DAG) dependent mechanism, will 
lead to the activation and translocation to the membrane of PKCs, which will act as a memory 
leading to protection [102, 125]. In fact, it has been proposed that the activation of PKCs requires 
the physical translocation of the enzymes to their docking sites [99]. However, the hypothesis that 
IP is the result of translocation of cytosolic PKC into the membranes has been challenged by 
other authors [198]. Although many studies have shown that various PKC isoforms are 
translocated in preconditioned myocardium, few have clearly and unequivocally correlated the 
translocation with the presence of a protected state. For a review on the translocation theory the 
reader may see [41]. 
The ROS/RNS formation is important; in fact ROS/RNS scavengers, given in this phase, will block 
preconditioning cardioprotection [2, 62, 146, 150, 199, 216, 217, 232, 235]. For example, scavenging of 
reactive species with ascorbic acid blunts the beneficial effect of ischemic preconditioning in pigs [199]. 
The ROS/RNS step explains why receptor population during ischemia without brief reperfusion does not 
protect. Although ROS can be formed also during ischemia, the brief reperfusion during preconditioning 
maneuvers is important for the re-introduction of oxygen and the formation of protective ROS/RNS. The 
origin of ROS/RNS and the role of ROS/RNS in I/R injury and cardioprotection will be considered more in 
deep in this brief review (see below). 
The pathways that lead from receptor activation to ROS/RNS formation are quite complex (Figure 2). 
Several studies used activators, blockers and proteomic analyses to reveal the signal transduction events 
between the membrane receptors and the production of ROS/RNS with a signaling role. The reader is 
referred to other excellent reviews on this area [193, 233]. The sequence of intracellular events is 
summarized below.  
The cardioprotection of ischemic preconditioning is induced by mechanical maneuvers (i.e. brief cycles of 
I/R) that trigger the release of various molecules (e.g. adenosine, acetylcholine, opiates and/or 
bradykinin). The cardioprotection can be also induced directly by the infusion of one of these agonists or 
other agents for few minutes; that is pharmacological preconditioning [80, 233]. The consequence of the 
coupling of some of these agonists to their receptors is the activation of phosphatidylinositol 3-kinase 
(PI3K) with a pivotal role of matrix-metalloproteinases in the transactivation of the epidermal growth 
factor receptor (EGFR). Briefly, the matrix metalloprotease may cleave the pro-heparin-binding EGF (pro-
HB-EGF) to liberate the soluble HB-EGF, which activates the EGFR resulting in EGFR dimerization. This 
leads to autophosphorylation of tyrosine residues on both EGFRs and binding of Src kinase to form a 
signaling module which activates PI3K [32, 63, 72, 114, 157, 207, 229]. 
Then PI3K activates protein kinase B (PKB or Akt) with the subsequent activation of nitric oxide synthase 
(NOS)/nitric oxide (NO
•
)/guanylyl cyclase (GC)/ guanosine monophosphate 3'5' (cGMP) pathway that in 
turn activates protein kinase G (PKG). PKG, in cooperation with intra-mitochondrial PKCε, will lead to 
mKATP channel opening, potassium entry and ROS/RNS formation. It seems that mKATP channel opening is 
first mediated by PKG phosphorylation of a mitochondrial outer membrane protein; thus leading to 
increased ROS, which then activate an intra-mitochondrial PKCε, which also phosphorylates mKATP 
channels and leave them in a prolonged open state [47, 64, 66]. This prolonged open state of mKATP may 
be co-responsible for “memory,” which is seen with all preconditioning [47]. ROS will spread out of the 
mitochondria and will lead to kinase activation, including PKCs, which may represent the memory effect. 
In this ROS formation and spreading may play an important role the presence of connexin 43 (Cx43) in 
the mitochondrial inner membrane [17, 62, 84, 160, 182, 184] (see also below).  
Therefore, in ischemic (memory) phase PKCs and possibly others kinases will act as a memory effect, 
which may include in the sensitization of the low-affinity A2b adenosine receptors (A2b-AR) [43]. 
Consequently, in reperfusion (mediator phase) A2bAR and other receptors can be reactivated by 
endogenous adenosine and other autacoids (e.g., bradykinin and opioids) released by the previously 
ischemic cardiomyocytes. In this way cardioprotective pathways can be activated in reperfusion to avoid 
mPTP opening. In fact, it has been reported that mPTP is maintained in a closed state during ischemia 
and in non-protected (naïve) hearts typically opens at reperfusion, when calcium overload, ROS/RNS 
stress and pH recovery all occur. These are consequential to the restoration of blood flow to the ischemic 
heart and they are all recognized as potent triggers that increase the open probability of the mPTP. The 
opening of these pores will lead to cell death by different mechanisms including mitochondrial 
destruction from mitochondrial swelling and membrane rupture and cytochrome-C release which 
induces programmed cell-death pathways [54, 148]. mPTP inhibition at the time of reperfusion appears 
pivotal to all strategies of cardioprotection thus far studied [18, 54] (Figure 3). However, despite intensive 
investigation, the precise molecular identity of the mPTP components remains unknown. Both the 
adenine nucleotide translocase (ANT) and the voltage-dependent anion channel (VDAC) are reported to 
be components of the mPTP, together with cyclophilin D (CyPD). Nevertheless, neither ANT nor VDAC 
seems to be an obligatory component of mPTP [8, 107]. Given the fact that mPTP structure remains 
elusive, mPTP inhibition is viewed with skepticism by some authors. With no doubts the identification of 
the actual molecular components of the mPTP may provide new strategies for mPTP inhibition and 
perhaps novel therapeutic targets for cardioprotection [77]. 
Therefore, given the importance of mPTP formation at reperfusion, one can speak of reperfusion injury: 
the damage that occurs typical in reperfusion phase. In other words, at reperfusion we can consider 
three populations of cells: 1) cells that were killed by ischemia, 2) cells that had sub-lethal injury and will 
survive, and 3) cells that are alive but will die from mitochondrial pore opening. These latter cells are the 
target of preconditioning and, as we will see, they are also the target of postconditioning. Hence, both 
pre- and post-conditioning limit reperfusion injury. 
The question arises: what inhibits transition pore opening? We will see the importance of the 
recruitment of protective pathways, such as the so-called Reperfusion Injury Salvage Kinases (RISK) 
pathway and Survival Activating Factor Enhancement (SAFE) pathway, the persistence of acidosis and 
possibly a new ROS/RNS signaling in reperfusion phase [78, 88, 90, 97, 151].  
What turns on PI3K and RISK pathway at reperfusion? The answer is: adenosine, bradykinin and other 
autacoids that accumulated during ischemia. For brevity we will concentrate on adenosine and 
bradykinin. 
The importance of adenosine in the reperfusion phase in preconditioned hearts has been demonstrated 
by the experiments of Solenkova et al.[202], who have shown that non-selective and selective adenosine 
receptor antagonists block preconditioning protection if given in reperfusion. Proteomic studies have also 
revealed the importance of PI3K/Akt and extracellular-signal-regulated kinase 1/2 (ERK1/2) which are 
considered the initiators of the RISK pathway [43, 78]. As said above, it is PKC that makes the 
preconditioned heart sensitive to its own adenosine. In fact, an activator of PKC given at reperfusion is 
able to induce protection, whereas both PKC antagonists and adenosine receptor blockers given at 
reperfusion abolish protection [171].  
Therefore, in a nutshell we can say that in preconditioning the protective maneuvers are performed 
before the infarcting ischemia, but the protection does not occur against ischemia only. The protection is 
mainly against the reperfusion injury. The repopulation of receptors by autacoids and the activation of 
multiple kinases of the so called RISK pathway are critical events leading to prevention of mPTP opening 
and cell death. In the trigger phase mKATP channels and ROS/RNS signaling are important players; the 
actual protection occurs in the reperfusion rather than the ischemic phase, and reactivation of adenosine 
receptors, ROS/RNS signaling and multiple kinases are critical events, which lead to prevention of mPTP 
opening and limitation of reperfusion injury. Of note, an antioxidant given early in reperfusion may abort 
the cardioprotection by preconditioning (see below).  
Some in the “cardioprotection community” might challenge various aspects of the above scenario. In this 
brief synopsis we cannot consider all the aspects and controversies on preconditioning. For instance, 
there are authors that challenged the role of autacoids, such as bradykinin [156] and researchers that 
even challenged the existence of diazoxide/glibenclamide-sensitive KATP channels in rat mitochondria 
[39]. There are also investigators that have failed to find any RISK-pathway relevance in preconditioning’s 
protection (this may be species-specific) [87, 200]. Moreover, it must be stressed that cardioprotection 
may also occur completely independent of RISK and SAFE pathways. For instance, neither modifications 
of RISK signaling nor those of SAFE signaling contributed to the increased tolerance to myocardial I/R 
injury usually induced by Cx43 deficiency [188]. Also matrix-metalloproteinase inhibition has been seen 
to be cardioprotective, independent of Akt/ERK/CyPD/mPTP activity and to be additive to the protection 
observed following inhibition of mPTP opening [14]. These data are indicative of redundant parallel 
pathway(s) to protection in ischemic/reperfused heart. The reader is kindly directed to several reviews 
on these pathways and controversies [e.g.  [81, 233]]. 
Points to be underlined:  
 How and when the IP stimulus generates the ROS signaling. 
It has been proposed that ROS may be produced during brief preconditioning ischemia and that these 
ischemia-generated ROS may play an important signaling role. Therefore ischemia-generated ROS could 
be the actual ROS that is triggering preconditioning [10, 225].  
Other authors are of the opinion that ROS that triggers protection are produced during the reperfusion 
phases of the preconditioning maneuvers [56].  
It seems that mitochondrial ROS generation and limitation of mPTP formation are connected in a 
protective signaling pathway located inside the mitochondria [79]. In fact loss of mitochondrial Cx43 
decreases ROS formation by Diazoxide, leading to a loss of pharmacological preconditioning-induced 
protection [84]. Moreover it has been suggested that PKG, PKCǫ1 and 2, mKATP opening, and Cx43 are all 
located within mitochondria and in concert regulate mitochondrial ROS production [47] Yet, it has been 
stressed that mPTP transient opening may be fundamental for the ROS signaling upon IP and 
pharmacological preconditioning with Diazoxide [76] or Isoproterenol [185]. However, the mitochondrial 
origin of protective ROS seems to be in contrast with the finding that nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase plays a pivotal role in ischemic preconditioning and that NADPH oxidase-
deficient mice cannot be preconditioned [13]. It cannot be excluded that cooperation exists between 
different sources of ROS in preconditioning. Nevertheless, the cooperation between different sources of 
ROS in triggering preconditioning is not universally accepted, and little agreement exists among scientists 
about the phase (ischemia or reperfusion) and the nature of ROS involved in preconditioning triggering 
[161]. 
 How ROS/RNS activate protein kinases 
Several studies indicate that the protein kinase activation events that are initiated by I/R can be 
reproduced by oxidative agents [3, 9, 39, 40, 170] suggesting that ROS/RNS are among the principal 
responsible for the reversible protein kinase activation observed subsequently to I/R. In fact, ROS/RNS 
may induce either reversible or irreversible oxidation of proteins/enzymes (Figure 4). Reversible 
modifications include, for instance, modifications of cysteine residues such as disulfides, sulfenamides, 
protein SNO and S-glutathionylation. Sulfenamides can be further oxidized to sulfinic or sulfonic acid, 
which are generally considered irreversible modifications [37]. Besides cysteine residues other targets of 
ROS may be iron-sulfide centers and zinc-finger domains of proteins. 
ROS, such as peroxide, may be responsible of kinase activation via tyrosine phosphorylation or via the 
induction of the release of zinc from zinc-finger domains of PKC [109, 110]. Besides kinase activation, the 
increased kinase activity and consequent phosphorylation may also be the result of the well-known 
inhibitor effect of ROS on phosphatases, whose enzymatic activity is abolished by oxidation of a cysteine 
residue in their active site [37, 186]. Alternatively, the PKC activation may be determined by a 
downstream product of hydroxyl radical, probably a product of phospholipid oxidation [66]. Protein 
kinase C activation, besides depending on redox action, is classically activated by lipid second 
messengers, such as DAG. Thus, one can wonder whether these two activation modes involve the same 
or alternate mechanisms. Recently, it has been suggested that both lipid activators and oxidation target 
the zinc-finger domains of PKC, supporting a unifying activation mechanism [238]. As reported above, 
PKCε activation contributes to the NO
• 
mediated cardioprotection. This activation has been associated 
with the tyrosine nitration of PKCε [9]. Thus, both nitration [9, 221] and S-nitrosylation [53] may be 
involved in direct kinase regulation. Hence, NO
•
 and RNS may interfere with tyrosine phosphorylation in 
several ways: 1) they can diminish the efficacy of a protein as a substrate for tyrosine kinases [71, 108], 
2a) can lead to their direct activation by increasing phosphorylation of kinases (e.g. focal adhesion kinase, 
Src kinase and mitogen activated protein kinases) [16, 136, 147] or 2b) by inactivating phosphatases 
[212]. 
Finally, we must consider that irreversibly oxided/nitrated proteins may be preferentially degraded via 
ubiquitin mediated pathways [203], which could determine the stability/activity of enzymes in cells. 
Therefore, while we highlight the activation of enzymes (e.g. kinases) by redox mechanisms, they could 
also affect the inhibition and/or degradation of other enzymes [164]. Clearly, much more work is needed 
to clarify the relative importance of each of the above proposed mechanisms. 
 How IP reduces the generation of detrimental ROS/RNS at reperfusion 
One of the major mechanisms for the limitation of the formation of detrimental ROS/RNS at reperfusion 
is the avoidance of the long lasting opening of mPTP and the consequent phenomenon termed ROS-
induced ROS release (RIRR). In fact mitochondria can respond to elevated ROS concentrations by 
increasing their own ROS production [25]. This oxidative stress is particularly exacerbated in the presence 
of pressure overload in ischemic-reperfused hearts    [137]. 
Long-lasting mPTP opening and RIRR are favored by several factors, including calcium overload and pH 
recovery. Also the constitutive NOSs are calcium-dependent. Therefore preconditioning, by limiting this 
calcium overload and pH recovery may prevent detrimental ROS/RNS at reperfusion [44, 80]. It is of note 
that NOS function is also dependent on redox conditions and its S-glutathionylation. This can be 
important in cell signaling and I/R; for a review see [242]. 
The translocation of protective factors of both RISK and SAFE pathways to mitochondria may activate 
intra-mitochondrial protective mechanisms and may contribute to the limitation of ROS formation by 
these organelles [80]. Of course the ROS that trigger RIRR may have a different origin (see below), 
therefore other mechanisms may play a role, such as modification of the activity of endogenous 
antioxidants. 
Remote preconditioning, a brief synopsis 
It is worthwhile to spend few words on remote ischemic preconditioning, which has different but also 
similar aspects to classical preconditioning and may have an important clinical application [82]. 
Transient non-lethal ischemia and reperfusion of an organ (remote organ) may confer resistance to a 
subsequent episode of lethal I/R injury in another target organ or tissue. This intriguing phenomenon is 
called remote ischemic preconditioning. It was originally described as an intramyocardial protection, 
which can be “transferred” from the myocardium served by one coronary artery to another [174]. Then it 
was demonstrated that myocardial injury can be drastically reduced by applying brief ischemia and 
reperfusion to an organ or tissue distant from the heart before the onset of myocardial ischemia [68, 
175]. Now we know that remote organ protection may be applied to several organs and may represent a 
general form of inter-organ protection against I/R injury, including also the limbs in humans. At least 
three hypotheses have been proposed to explain the occurrence of remote ischemic preconditioning 
[82]. A first hypothesis (neural hypothesis) considers the release of local autacoids at the site of remote 
preconditioning that in turn trigger neuronal reflexes protecting the target organ. The second hypothesis 
(humoral hypothesis) proposes that humoral factors (e.g. adenosine, Angiotensin I, bradykinin, CGRP, 
endocannabinoids, erythropoietin and opioids) or some as yet unidentified endogenous substance(s) 
generated in the remote organ or tissue. These are then carried through the circulation to the site of I/R 
injury where they exert their effects recruiting the various pathways of cardioprotection implicated in 
preconditioning. The third hypothesis (systemic hypothesis) suggests that transient ischemia and 
reperfusion of an organ provokes a systemic protective response, which suppresses inflammation and 
apoptosis [82]. A role for ROS signaling in the remote organ and a reduction of redox stress in the target 
organ has been also proposed [93, 194]. In particular, it appears that remote ischemic preconditioning is 
triggered by a combination of increased NO
•
 synthesis, opening of mKATP channels and increased ROS 
production in remote tissue. Moreover, it seems that NO
•
 is working upstream and acts via activation of 
mKATP channels, which subsequently increases the production of ROS [93, 194]. Of note, it has been 
suggested that in man the activation of a single cell surface receptor may be sufficient to trigger 
preconditioning, while blockade of multiple pathways may be required to abolish the protective effect of 
remote preconditioning [156]. In fact, a recent study does not support a role for endogenous bradykinin 
as a mediator of I/R injury or remote ischemic preconditioning in human arms. In particular, these 
authors have demonstrated that systemic administration of a bradykinin B2 receptor antagonist has no 
effect on the endothelial vasomotor dysfunction induced by I/R injury or the protection conferred by 
remote ischemic preconditioning [156]. 
Postconditioning, a brief synopsis 
Preconditioning can be useful in programmed cardio-surgery interventions. However, it is not useful in 
the patient with acute myocardial infarction because it must be instituted prior to ischemia [201]. What 
solved this quandary was the most improbable discovery that multiple cycles of reperfusion/ischemia 
after an infarcting ischemia could also induce a potent protection against I/R injury. This phenomenon 
has been called postconditioning and it opened a new avenue of research [240].  
It is now clear that ischemic postconditioning reduces: infarct size, post-ischemic arrhythmias, apoptosis, 
endothelial-dysfunction and -activation. However it is not clear if it can reduce myocardial stunning [151, 
164, 166] (Figure 1). 
Initially, ischemic postconditioning was attributed to passive mechanisms, which considered 
postconditioning as a sort of gradual reperfusion leading to a reduced accumulation of neutrophils and a 
reduced ROS/RNS stress. This would reduce calcium overload and cell death [240]. 
However, it was soon clear that postconditioning is able to activate intrinsic protective pathways. This 
was demonstrated almost simultaneously by us and the group of Yellon using an isolated buffer perfuse 
heart model, in which, of course, there were no leucocytes: for this reason active intra-myocardial 
mechanisms have been highlighted [153, 218]. 
The picture about postconditioning cardioprotection includes now passive and active mechanisms that 
lead to prevention of mPTP opening and cardioprotection. Again the RISK pathway is involved [78] 
(Figure 5). We have shown that postconditioning is NOS and guanylyl cyclase dependent [158]. Most 
importantly, it has been shown that if we delay postconditioning maneuvers just for few minutes PostC is 
not longer protective [104]. The relevant time-window may be species-specific and may be conditioned 
by concomitant diseases and by the suited end-point (infarct size, stunning or arrhythmias) [201]. 
A few years after the discovery of postconditioning phenomenon we made “a really radical observation”: 
ROS/RNS signaling is protective in early reperfusion [167].  
ROS/RNS are required in early reperfusion to trigger protection via PKC and mKATP activation. In fact cell 
permeant ROS-scavengers, an mKATP antagonist or a PKC blocker given in early reperfusion block 
postconditioning’s protection [167]. In other words postconditioning also uses the same steps seen in 
preconditioning trigger pathway. “A really radical observation” is the expression used by Cohen and 
Downey when they wrote a comment on our article and confirmed our proposal that ROS do trigger 
postconditioning’s protection using a similar model [57]. We confirmed the importance of ROS/RNS also 
in bradykinin induced postconditioning [160]. The importance of ROS/RNS in postconditioning 
cardioprotection obtained with brief intermittent ischemic periods or pharmacological tools has been 
confirmed by other authors, in vivo[44]. 
A very important role in postconditioning cardioprotection may be played by the delayed intracellular pH 
recovery in postconditioned heart [97] (Figure 5). In fact, many research groups have proposed that 
postconditioning protects because it maintains acidosis during early reoxygenation which inhibits mPTP 
opening, directly or indirectly via calpain inhibition, and allows ROS/RNS signaling. This gives the heart 
enough time to trigger cardioprotective pathways and to “precondition itself” against reperfusion injury. 
In fact, in the absence of acidosis in early reperfusion (i.e. when pH recovers freely and swiftly) there is an 
over production of deleterious ROS. Instead the acidosis, limits, but does not eliminate, ROS production. 
Incidentally, this reduced ROS production is mandatory to trigger the cardioprotective processes. In fact, 
if the ROS production is impaired with the addition of antioxidants in this phase the protective 
maneuvers are ineffective (see below). Recently, the groups of Yellon and Downey have proposed that in 
preconditioning there is also a delayed recovery of pH and a ROS signaling in early reperfusion [81, 115]. 
We have shown the importance of bradykinin receptors [160], while the groups of Downey [42] and 
Vinten-Johansen [103] have shown the importance of different adenosine type 2 receptors subtypes in 
postconditioning. 
Since the delayed recovery of pH has been given so much importance, the question arises: is acidic 
perfusion protective in early reperfusion? The answer is yes: brief acidosis in early reperfusion (BAER) is 
as protective as postconditioning. However, some concerns derive from the possibility that it might 
increase arrhythmias [183]. This observation might be species-specific and is in contrast with the strong 
anti-arrhythmic effect of postconditioning obtained with intermittent reperfusion/ischemia. In fact, acidic 
reperfusion reduces the incidence of ventricular fibrillation in rat heart models of regional ischemia [5, 
95], and there are early reports which propose brief intermittent I/R as a maneuver against ventricular 
arrhythmias in reperfusion in different species [65, 105, 141], including pigs [96] and humans [73]. The 
ROS-dependent protection of BAER has been also demonstrated by Downey Group [45]. We have also 
confirmed that BAER is protective and that this protection can be avoided by a ROS-scavenger [165]. 
Moreover, we have shown that in postconditioning and acidosis the reaction of NO
•
 with ROS to form 
RNS switches from Nitration to S-nitrosylation (SNO) of proteins [165]. In fact, 3-nitrotirosine levels are 
reduced and S-Nitrosylated proteins are increased at the 10
th
 min of reperfusion. As a matter of fact, it is 
now believed that SNO of critical proteins plays a very important role in nitric-oxide dependent 
cardioprotection. SNO of many proteins has been found in mitochondria [138] (see also below). 
Nevertheless, PostC increased cardiac 3-nitrotyrosine concentration in the normal but not in the 
cholesterol-fed heart when measured at the 5
th
 min of reperfusion. These data suggest that a balance 
between nitrosative stress and S-nitrosylation is involved in the triggering mechanism of PostC and that 
comorbidities may cause the loss of the cardioprotective effect of PostC, at least in part, via deterioration 
of the nitrosative trigger [116]. 
To sum up “pre- and post-conditioning are united at reperfusion” [78] with the important role of 
physiological mechanisms such as acidosis, ROS/RNS signaling and RISK activation. Importantly, 
pharmacological postconditioning can protect the heart, but this must be applied very soon in 
reperfusion, because the first minutes of reperfusion are critically important. The low pH during the 
postconditioning cycles prevents transition pore opening, mitochondria can make the right ROS/RNS to 
activate PKC and put the heart into a protected state; then PKC activates pathways that prevent 
transition pore opening after the pH is normalized. 
As stated, there is another parallel pathway activated by pre and post-conditioning. This is SAFE pathway 
(Figures 2 and 5), which includes the activation of the cytokine tumor necrosis factor alpha (TNFα) and 
the transcription factor signal transducer and activator of transcription-3 (STAT-3). SAFE is now 
recognized as a pathway that can confer protection in ischemic pre and post-conditioning independently 
from RISK pathway. Nevertheless these two apparently parallel pathways (RISK and SAFE) may cross talk 
and both converge on mitochondria [78]. Whether all protective strategies activate both RISK and SAFE 
pathways, or alternatively some strategies may activate one or the other, it is not clear at moment. For 
instance, we have evidences that ischemic PostC may activate both RISK and SAFE pathway. However, 
PostC with Diazoxide (an activator of mKATP channels) may trigger a redox-sensitive translocation to 
mitochondria of RISK elements only. Thus protection by Diazoxide does not need SAFE pathway 
activation [163]. 
We have seen the importance of acidosis, ROS/RNS signaling and protective pathways that prevent mPTP 
opening in early reperfusion. Protective pathways have mitochondria as point of convergence. The hope 
is that the discovery of these major components of protection may help to identify novel 
pharmacological targets for protecting the ischemic heart at the time of myocardial reperfusion. 
Point to be underlined: 
How the PostC stimulus generates the ROS signaling at reperfusion- given the overwhelming 
presence of detrimental ROS at this time 
To address this issue, perhaps the best way is to report a paragraph of the Editorial of James M. Downey 
and Michael V. Cohen [57]:  
 “One of our fellows asked if testing a free radical scavenger in postconditioning might be a 
worthwhile experiment. We quickly chastised him explaining that the Paul Schumacker’s group had 
shown that the ROS burst during mKATP opening is less than a tenth of what is seen at reoxygenation after 
simulated lethal ischemia [232]. Any ROS produced by mitochondria following a prolonged period of 
ischemia would be like a sneeze in a hurricane – too small to be noticed. We assured him that we had to 
look elsewhere for what postconditioning does. We were wrong again! Penna and colleagues actually did 
our fellow’s experiment and postconditioned their rat hearts in the presence of the cell permeant ROS 
scavenger N-acetyl-cysteine. Of course, it blocked protection and their results are published in this issue of 
Basic Research in Cardiology [167]. After reading this paper we finally tried the same intervention in our 
rabbit model with the same result. Penna and colleagues completed the story when they also found that 
PKC inhibitors aborted protection. The data in this paper imply that during postconditioning the heart 
literally preconditions itself! We guess that the low pH during the postconditioning cycles prevents mPTP 
opening, while the intermittent oxygen bursts allow mitochondria to make enough ROS to activate PKC 
and put the heart into a protected state. PKC then activates pathways to keep the transition pores from 
forming after the pH is normalized. Why don’t the high levels of free radicals normally produced after 
release of a coronary occlusion do the job? Two possibilities come to mind. First their concentration may 
be too high to activate PKC without also directly causing transition pore opening at the same time. The 
second is that the wrong kind of radical may be produced by simple reperfusion”. 
It is now clear that in early reperfusion there is a redox signaling both in preconditioning [44] and 
postconditioning process [44, 167, 219] that it is best not to be disturbed for an appropriate protection. 
We are of the idea that both possibilities suggested by Downey and Cohen [57] are responsible of 
postconditioning protection. 
Other possibilities of protection with brief ischemia are remote perconditioning (also called remote peri-
conditioning) and remote postconditioning. The first can be defined as “the induction of brief, repetitive 
interruptions of blood flow at a remote site, simultaneously with sustained target organ ischemia” and 
the latter as “the induction of brief, repetitive interruptions of blood flow at a remote site, immediately 
after the target organ ischemia” [211]. Although, as above reported, several studies demonstrated a key 
role of ROS signaling in the mechanism of both pre- and post-conditioning procedures during the early 
phase of reperfusion [45, 57, 81, 124, 160, 161, 167, 219], it is not clear whether remote per- and post-
conditioning include a protective role of ROS signaling during reperfusion and whether this signal occurs 
in remote or target organ [126, 191, 239]. However, very few studies considered these two procedures 
(remote per- and post-conditioning) and further investigations are required to reach a conclusion on 
whether or not a ROS signaling in either remote or target organ is needed. 
 
ROS may be good or bad depending on the environment 
We have seen the central role of ROS in cardioprotection. Let’s consider now some of the features that 
can make ROS good or bad. First of all let's make it clear that it is not possible to subdivide the various 
ROS as good or bad without taking into account their chemistry and the biological environment in which 
they operate. In fact, the reactive species that were classically considered as very bad (i.e. peroxynitrite 
and hydroxyl radical) are now considered responsible of some important steps in cardioprotection: see 
for example the works of Kupai et al. [116] and Garlid et al. [66]; see also below. 
Normal metabolism is dependent upon a ROS, oxygen. The two unpaired electrons of oxygen spin in the 
same direction; thus oxygen is a bi-radical, but it is not a very dangerous radical. Other oxygen-derived 
free radical species, such as superoxide anion (O2
-•
) and hydroxyl radical (OH
•
), or hydrogen peroxide 
(H2O2), are stronger oxidants and therefore potentially more dangerous. However, these ROS are 
normally produced during oxidative metabolism and energy production by the cells. They are involved in 
several processes such as, electron transport in mitochondria, enzyme-catalyzed reactions, signal 
transduction and gene expression. They are also involved in the activation of nuclear transcription 
factors, oxidative damage to molecules, cells and tissues, as well as in antimicrobial action and in long 
term processes of aging and inflammatory/degenerative diseases [10, 31, 58, 83, 91, 161]. 
Nitric oxide is another radical that can be produced by enzymatic and non-enzymatic reactions in the 
biological systems [196, 224]. Despite its radical nature, NO
•
 may have antioxidant properties [228, 229]. 
The antioxidant properties of NO
•
 can be also inferred by recent intriguing experimental models 
introduced by the group of Roberto Bolli. They used a mouse model of cardiomyocyte-restricted 
overexpression of extracellular superoxide dismutase (ecSOD) [199] and a model with inducible NOS 
(iNOS) gene transfer [121]. In the model with cardiac-specific ecSOD overexpression, they observed an 
attenuated levels of ROS which was attributed to increased NO
•
 availability in response to I/R leading to 
protection against reperfusion injury [199].In the model with iNOS gene transfer, they observed long-
term (1 year) cardioprotection against I/R injury, without negative functional consequences [121]. 
However caution must be used in the interpretation and translation to the clinic of this approach. In fact, 
iNOS expression in peripheral blood cells may mediate myocardial I/R injury [74]. 
It is well known that NO
•
 modulates cell function by activation of soluble GC (sGC) to form cGMP. 
However, in addition to activating cGMP-dependent signaling pathways, NO
• 
nitrosylates target proteins, 
which consists in the covalent attachment of an NO-moiety to a nucleophilic protein sulfhydryl resulting 
in S-nitrosothiol formation. Actually, NO
•
 is involved in several processes of pro-oxidation or anti-
oxidation, as well as in a cornucopia of reaction leading to processes of nitrosation/nitrosylation or 
alternatively to processes of nitration to form RNS [151] (see below).  
 
Point to be underlined: 
How, why and when the role of ROS and RNS changes from physiological cell signaling into 
pathological contribution to disease 
Both ROS and RNS are involved in normal cell regulation in which oxidants and redox status are 
important in signal transduction. Oxidative stress is increasingly seen as a major upstream component in 
virtually all pathological processes, such as inflammatory responses, cytostatic effects and cell death 
(apoptosis, necrosis and/or necroptosis), where ROS/RNS may be causal and/or secondary to the disease 
process [10, 151, 161, 164]. The biochemistry and biology of ROS/RNS is particularly complicated and it is 
not easy to differentiate a clear border between beneficial and deleterious effects. However, to simplify 
the concepts, we can consider beneficial those reactions involving ROS/RNS that lead to short-lasting and 
reversible modifications of the targeted component, such as proteins, nucleic acids and lipids, so that we 
can speak of redox signaling. For example the effects of NO
• 
can be separated in two basic categories, 
direct and indirect effects [120, 230]. Usually direct effects are reversible and are mediated by NO
•
 when 
it binds directly to a site on the target molecule (e.g., the reaction between NO
• 
and heme-containing 
proteins). These reactions are generally rapid and require submicromolar concentration of NO
•
. On the 
contrary we can consider those reactions that are long lasting and/or irreversible as deleterious (usually 
indirect reactions). They may damage targets that will compromise cell and organ function, so that we 




indirect effects may fall in this category when great 
concentrations of NO
• 
(greater than 1 microM) reacts first with ROS and then with DNA inducing 
irreversible modification and damage leading to mutations [230]. 
Of course the above is an oversimplification; in fact for example, we can have redox processes that 
damage a protein that is subsequently removed by the proteasome and/or autophagy and ultimately 
result in protection of the cell. For example, autophagy is very important in cardioprotection [70]. It is a 
physiological mechanism that comprises a group of processes, involving degradation of macromolecular 
complexes and organelles within the vacuole or the lysosome. During autophagy the cell can recycle 
obsolete cellular constituents and eliminate damaged organelles and protein aggregates [94, 226]. In the 
heart, autophagy is upregulated by ROS, hypoxia, and ischemic preconditioning. Thus, this ROS-
dependent physiological mechanism plays a key role in enhancing the heart's tolerance to ischemia. In 
fact the upregulation of autophagy confers cardioprotection against I/R injury, whereas its inhibition is 
associated with a loss of protection conferred by pharmacological preconditioning [70].  
Moreover, some ROS/RNS that is considered “bad or ugly”, may be involved in inducing important 
protective signaling. This is the case, for instance, of peroxynitrite, which is classically considered “bad”, 
but it is also responsible of the triggering of cardioprotection [116] (see also below). Nevertheless, both 
ROS and RNS can directly react with glutathione to lower the levels of this substance, the cell’s primary 
antioxidant. So that changes in redox status and depletion of antioxidants occurring during frank 
oxidative stress may be revealed by the thiol redox status. In fact oxidized glutathione (glutathione 
disulfide, GSSG) accumulates under conditions of oxidant exposure, and this alters the ratio of oxidized to 
reduced glutathione (GSH): an increased GSSG/GSH ratio may indicate oxidative stress. 
Finally, S-nitrosylation may represent a shield against oxidative stress, so that nitrosylated protein may 
protect cells from an irreversible oxidation and a burst of ROS/RNS [138]. This shielding effect of S-
nitrosylated proteins may occur, for instance, in the first seconds of reperfusion during PostC maneuvers 
[165]. S-nitrosylation of proteins is emerging as a multifaceted post-translational modification. Since SNO 
is the result of a transient reaction, it can either act as a signaling molecule itself or as an intermediate 
leading to other modifications. Moreover, specific SNO can play a role when occurring in a single cysteine 
site, such as calcium channels [123] and mitochondrial VDAC [163]; additionally it may have a role within 
the context of other SNO sites and other post-translational modifications [139, 151, 164]. In particular, 
SNO of some proteins has been suggested to reduce ROS generation, such as in the case of SNO and 
inhibition of mitochondrial complex I. In fact, compartmentalization and SNO occupancy may play an 
important role in the consequences of the protein SNO modifications [29, 127, 197, 214]. It seems that 
SNO carries promising implications for cardiac protection, which, however, needs future study to be 
further detailed and corroborated. 
Sources of ROS and RNS: reactive oxygen and nitrogen species are products of multiple enzymes and 
reactions within and outside the cells. These are described below and illustrated in Figure 5. 
In cardiomyocytes the principal source of ROS is the mitochondrion. Thirty percent of the cardiomyocyte’s 
volume is occupied by mitochondria. They are localized under sarcolemma (subsarcolemmal 
mitochondria) and between myofilaments (intermyofibrillars mitochondria), closely related to the 
sarcoplasmic reticulum (SR) and also clustered around the nucleus. Such an organization facilitates the 
functional interplay between mitochondrial ATP production, membrane function, SR-regulated Ca
2+
 
homeostasis and myofilament dependent contraction [111, 181]. Intriguingly, subsarcolemmal and 
intermyofibrillars mitochondria have different composition and respond differently to Diazoxide, a drug 
supposed to promote ROS signaling through actions on mKATP channels, probably because of the absence 
of Cx43 in the intermyofibrillars mitochondria [18, 19, 84, 92, 182, 188]. 
During respiration, mitochondria produce ATP and ROS; within mitochondria the O2
-•
 is the immediate 
product of multiple enzymes, including the enzymes and other components (e.g., iron-sulfur clusters, 
quinones and cytochromes) of mitochondrial oxidative phosphorylation. It seems that O2
-•
 is mainly 
generated at complexes I and III of the electron transport chain (ETC). Apart from the ETC, there are 
other sources of ROS in mitochondria, for example, enzyme systems such as 2-oxoglutarate, pyruvate 
dehydrogenase, and flavoprotein acyl-CoA dehydrogenase [113, 204]. While superoxide is continuously 
produced by respiring mitochondria, H2O2 is rapidly generated due to spontaneous and enzymatic O2
-•
 
dismutation by Mn-SOD. Moreover H2O2 can be directly formed by the action of p66Shc and monoamine 
oxidases. H2O2 can affect cell function by reacting with thiol residues in redox-sensitive proteins in either 
the mitochondria or cytoplasm. In fact, while H2O2 easily crosses the biological membranes, the 
negatively charged O2
-•
 does not permeate the lipid bilayer of membranes. However, we should keep in 
mind that O2
-•
 is able to pass through the pore of anion channels (AC), such as voltage-dependent 
mitochondrial anion channel (Figure 6). 
Under redox balanced conditions, mitochondrial H2O2 production is limited by the scavenging capacity of 
the GSH and thioredoxin-2 (Trx2) antioxidant systems [48, 180]. The H2O2 scavenger, catalase, is present 
in very low concentrations in the mitochondria [177, 187] When the rate of ROS production exceeds the 
scavenging capacity of the antioxidant systems H2O2 can be transformed to the more dangerous OH
•
, 
which, however, when formed transiently and in small amounts may be protective [66].  
The importance of the role of a balanced production of ROS within mitochondria may be inferred from 
studies in genetically-altered mice in which mitochondrial antioxidant levels have been modified.  
Transgenic mice overexpressing mitochondrial peroxiredoxin III [134]  or glutathione peroxidase [195] 
have shown a significant attenuation of post-ischemic adverse left ventricular remodeling. Similarly, mice 
with a mitochondrial-targeted overexpression of catalase have demonstrated a prolonged life span with 
improved cardiac function [192] and an attenuation of cardiac aging [50]. In contrast, mice with ablation 
of either the Trx2 or thioredoxin-reductase-2 gene confers a lethal embryonic phenotype [46, 144], and 
cardiac tissue-restricted ablation of TrxR2 results in fatal dilated cardiomyopathy [46]. Mice with 
complete deletion of mitochondrial Mn-SOD develop severe fatal dilated cardiomyopathy [122]. All 
together these data demonstrate that mitochondria have an enzymatic kit that will potentially produce 
toxic amounts of ROS, but at the same time they have the ability to mitigate their toxicity. In general, we 
can understand that there is a delicate balance between pro- and anti-oxidants and that when this 
balance is perturbed toxic effects prevail; otherwise ROS can have beneficial effects. There are a plethora 







]i levels and pH, as well as intracellular compartments, to mention only few. Of course, we cannot 
consider in the detail the role of the single factor to determine the threshold separating beneficial from 
detrimental effects in this minireview, and the reader is aware of the complexity of the topic, which 
needs much more research. 
NO-synthases may be coupled or uncoupled 
Nitric oxide is produced by coupled NOSs, which convert L-arginine into L-cytrullin in the presence of O2 
and co-factors, such as flavins (FAD and FMN), NADPH and tetrahydrobiopterin. Nitric oxide production 
by NOS is believed to be regulated by the docking of the FMN domain in one subunit of the dimer onto 
the heme domain of the adjacent subunit. There are three different isoforms of NOS in the heart: 
cardiomyocytes constitutively express both neuronal and endothelial NOS isoforms (nNOS and eNOS, 
respectively), whereas iNOS isoform may be expressed in various pathophysiologic situations. These NOS 
isoforms are localized to different microdomains in the cardiomyocytes, and are linked to selective 
signaling that is further impacted by heart disease. For instance, while eNOS is involved with cGMP-
dependent modulation of β-adrenergic stimuli, nNOS is linked to sarcoplasmic reticular calcium cycling 
(the reader is kindly directed to specific reviews on this topic) [24, 34, 128, 190]. In this context, it is 
useful to recall that iNOS may play a protective role in the so called second window of protection of 
preconditioning [22, 121, 149] 
A major post-translational cause of these enzymes pathophysiology is NOS-uncoupling. In fact, NOSs may 







. NOS-uncoupling occurs under certain conditions such as scarcity or absence of the cofactor, 
tetrahydrobiopterin, and/or of the substrate, L-arginine, as well as in the presence of oxidation of the 
Zn
2+
-thiolate center of NOS homodimer. NOS catalytic activity becomes ‘‘uncoupled’’ when the coupling 
between the reductase domain and L-arginine oxidation at the active site is lost and electron transfer 





seems that supplementation with tetrahydrobiopterin may reverse NOS-uncoupling in some 
cardiovascular conditions [34]. 
Under stress conditions, eNOS translocates from the sarcolemma to the mitochondria [209] with an 
essential role of lipid rafts [51] or signalosomes [176]. There is still an ongoing debate on whether 
mitochondria also contain functional NOS (for review see: [172]) and contribute to overall NO
• 
generation 
in cardiomyocytes [24]. 
Also NOS independent mechanisms may generate NO
• 
[244] .For instance, nitrite can be a source of NO
• 
via several reduction mechanisms both under acidotic and highly reduced conditions [119, 245] as well as 
in normoxia if a sufficient amount of nitrite is available [243]. Moreover, heme-containing proteins, such 
as myoglobin, may be responsible for nitrite-dependent NO
• 
production [85]. Recently, it was reported 
that another hemeprotein, Cytoglobin (an ubiquitous protein with an important role in 
oxidative/nitrosative signaling), mediates nitrite reduction and can play an important role in NO
•
 
generation and sGC activation under hypoxic conditions [118]. NO
•
 may also be generated by the 
xanthine oxidoreductase [228]. Within mitochondria, the cytochrome-C oxidase forms nitrite from NO
• 
during normoxia [190], but will generate NO
•
 from nitrite during low oxygen tension and low pH [35]. In 
the presence of hypoxia, acidosis and reduced mitochondrial membrane potential, NO
• 
formation 
through NOS isoforms declines. In fact, in vivo the NO
•
 concentration during low-flow ischemia remains 
unaffected by the pharmacological blockade of NOS [132], supporting a NOS-independent NO
•
 formation 
in these conditions. For a more exhaustive list of enzymatic and non-enzymatic pathways for this 
endogenous reduction of nitrite see the reviews of Zweier JL and Gladwin MT groups [224, 243].  
NO
• 
 signaling depends upon sGC activation and cGMP formation, with the consequent action on cGMP-
dependent enzymes (protein kinases and phosphodiesterases). However, the understanding of the 
importance of the so-called cGMP-independent NO
• 
signaling is increasing. These also include NO
•
 
binding to cytochrome-C oxidase in the mitochondria and its functional consequences, and are mostly 




. As a matter of 
fact, O2
-• 
can react with NO
• 
to generate peroxynitrite (ONOO
-
) and other RNS (via non-enzymatic 
reactions limited only by diffusion). These are a quite complex reactions and controversy exists on 




is bell-shaped or not [100, 241]. It seems that, in the absence of 
scavengers, ONOO
-
 decomposes to yield nitrate (NO3
-
) and free radical intermediates: hydroxyl radical 
and nitrogen dioxide. In most biological systems, carbon dioxide is a likely scavenger of ONOO
-
, yielding a 
short-lived nitrosoperoxycarbonate anion (ONOOCO2
-
). During the decomposition of ONOOCO2
-
, nitrate 
and carbon dioxide are formed, as well as nitrogen dioxide radical and carbonate radical anion (CO3
•-
). 






, is very fast and peroxynitrite is considered the 
major effector of nitrosative stress, which may modify the effect of NO
•
 from protective to deleterious 
[60]. Although it is widely accepted that enhanced ONOO
-
 formation is cytotoxic via nitrosative stress, 
physiologic levels of peroxynitrite may contribute to regulation of normal cellular functions via SNO of 
proteins, including mitochondrial (e.g. CyPD) and non-mitochondrial proteins (e.g. SERCA) [60, 69].  
Nevertheless, it seems that many, or even the most, effects of NO
•
 are mediated by SNO of proteins, 
which is a covalent modification of a protein cysteine thiol by an NO-group that generates an S-
nitrosothiol. It seems that environments that allow a transient nitration with a subsequent shift toward 
SNO of proteins may favor cardioprotection [165]. An increase of protein SNO has also been found to be 
necessary in nitrite-mediated cardioprotection. Yet, as seen above, NO
•
 can derive from nitrite under 
acidic conditions that occur during preconditioning ischemia, and this non-enzymatically generated NO
•
 
would not be blunted by NOS inhibitors [168, 197, 208]. A number of S-nitrosylated proteins have been 
identified in cardiomyocytes [60, 69, 106, 138] and cardiomyocyte mitochondria [138, 165, 172]. Since 
SNO can be reversed by intracellular reductants such as glutathione or ascorbate [6], as well as by SOD 
[101, 210] dynamic S-nitrosylation/de-nitrosylation reactions seem essential in cardiovascular regulation 
[12]. 
NADPH oxidase 
The Nox family NADPH oxidases are important sources of ROS also in the myocardium. Seven oxidase 
family members, which have distinct catalytic subunit (i.e., Nox-1-5 and Duox1 and 2) and different 
additional protein subunits, have been described (for reviews see [11, 117, 189]). The two Nox isoforms 
which are importantly expressed and have functional effects in cardiac myocytes are Nox2 [15] and Nox4 
[1, 30]. It seems that activated Nox2 is located predominantly on the plasma membrane, whereas Nox4 is 
found in cellular organelles [28, 36, 55, 220]. In particular, a mitochondrial and an endoplasmic reticulum 
(ER)-related perinuclear location has been described for Nox4 [1, 236]. Nox2 is normally quiescent and is 
acutely activated by various stimuli [11, 223]. Yet, Nox4 may be regarded as a slowly inducible isoform. In 
fact, Nox4 has constitutive low-level activity, and seems to be regulated largely by changes in its 
expression level [11, 26, 117, 223]. While Nox2 generates predominantly O2
•−
, Nox4 may generate 
predominantly H2O2 [55, 143]. 
The downstream effects of these two Nox isoforms seem divergent, with Nox2 mediating detrimental 
effects (redox stress), whereas Nox4 may facilitate beneficial processes (redox signaling) such as 
angiogenesis and adaptive hypertrophy. Using mouse models with selective gain and loss of function for 
these Nox isoforms, it has been suggested that a very different role is played by each one, roles that 
themselves vary depending upon the disease condition. For instance, deletion of Nox2 is protective 
against angiotensin II-induced cardiac fibrosis and hypertrophy, whereas deletion of Nox4 is detrimental. 
However, it should be noted that recent studies suggest that high levels of Nox4 may have detrimental 
effects via O2
•−
 production. The reasons for this discrepancy remain to be elucidated (for reviews see [11, 
117, 189, 237]). 
 
Summary of Redox-Stress and Redox-Signaling in the Context of Cardioprotection 
From the above description it is inferred that ROS/RNS may be detrimental (redox stress) or beneficial 
(redox-signaling). Irreversible oxidation of the target molecule is common during redox-stress, such as 
those occurring in lipid peroxidation. In contrast, redox-signaling entails one or more reactions, which are 
usually reversible and involve the oxidation of a signaling molecule by a reactive species. In other words, 
in redox-signaling, the reaction of the ROS/RNS with the target(s) is reminiscent of “on-off” signaling 
similar to phosphorylation. Among reversible redox signaling SNO of proteins is particularly relevant. It is 
a labile modification, and may be modified by the de-nitrosylation process. This consists of the removal 
of the nitroso-group and is an important aspect of S-nitrosylation signaling. In fact de-nitrosylation may 
limit the amount of nitrosylated proteins in order to avoid ‘excessive’’ S-nitrosylation, as can occur, for 
instance, when iNOS is produced. The de-nitrosylation was firstly considered as a spontaneous and non-
regulated process. Recently several non-enzymatic and enzymatic mechanisms of de-nitrosylation have 
been described in vitro and in vivo [for reviews see [133, 138, 205, 210] (see also below for the role of 
SNO in cardioprotection). 
Several excellent reviews have published evidence supporting a role for ROS and RNS in cell signaling, 
described the general properties that define a second messenger and showed how ROS and RNS fit into 
this role [58, 61, 135, 169, 178, 230, 231]. As seen above ROS/RNS can be synthesized within or outside 
the mitochondria. Whatever the case, either redox-stress or redox-signaling can occur on both sides of 
mitochondrial membranes. Redox signaling can occur by mitochondria releasing H2O2 that modulates the 
activity of target proteins through the reversible oxidation of critical protein thiols [7, 142], thus altering 
the activity of enzymes, kinases, phosphatases and transcription factors in mitochondria, cytosol or 
nucleus [151]. Although it is beyond the aim of the present review, it is necessary to recall that the redox 
control of phosphatases and kinases is of paramount importance in the biological systems, see for 
example [23, 179] . 
It must be borne in mind that the switch from redox-signaling to redox-stress (within and outside 
mitochondria) does not depend only by the type of ROS/RNS, but it also depend on amount of ROS/RNS 
and the vicinity of targets and antioxidants. Several isoforms of SOD degrade O2
-• 
to H2O2, including 
manganese SOD (MnSOD) in the matrix, and copper/zinc SOD (CuZnSOD) in the intermembrane space 
and cytosol. In the matrix, H2O2 is further detoxified to water primarily by glutathione peroxidase and 
catalase. Nevertheless, transient OH
• 
formation may be one step in a protective pathway [66]. 
Although excessive ROS/RNS formation during reperfusion that follows infarcting ischemia may enhance 
cell death, ROS/RNS signaling during early reperfusion is essential for the protection by ischemic and 
some pharmacological pre- and post-conditioning. As outlined above, ROS/RNS signaling before index 
ischemia, i.e., during brief pre-conditioning-ischemia [10, 223], and/or during the following reperfusion
 
[56, 161] is clearly involved in the triggering of IP protection against I/R injury. ROS/RNS signaling is also 
involved in the mediation phase of IP and in the triggering of PostC in the early reperfusion of 
conditioned hearts [44, 81, 124, 167]. For instance, beta-adrenergic preconditioning elicited by transient 
administration of Isoproterenol in rat hearts is dependent on generation of ROS during the triggering and 
mediation phases [185]. As mentioned above, opening of mKATP may be of pivotal importance for 
cardioprotection with pre- and post-conditioning protocols. The opening of mKATP channels may involve 
Cx43 and may be upstream of ROS/RNS signaling. In fact, it has been demonstrated that Diazoxide (a 
drug supposed to cause protection by increasing ROS production through actions on mKATP channels) may 
induce both pre- and postconditioning protection [62, 84, 160]. However, replacement of Cx43 by Cx32 in 
mice is characterized by loss of preconditioning protection, in particular when induced by Diazoxide 
[184]. Moreover, the failure of cardiomyocytes from Cx43
+/-
 mice to be protected by Diazoxide, has been 
attributed to the attenuated ROS generation [84]. This last effect may be related to absence of Cx43 at 
the inner mitochondrial membrane of cardiomyocytes from these animals [17, 182]. Therefore, mKATP 
channel opening is upstream of ROS generation. It is thus likely that these ROS may cross the 
mitochondrial membrane and may react with NO
•
 to form RNS thus contributing to protection. 
Cardioprotective procedures delay the post-ischemic recovery of intracellular pH that might prevent 
mPTP opening directly and indirectly (i.e., by inhibiting calpain activation). In addition mPTP opening 
might be further prevented by a ROS/RNS signaling that appears to depend on acidosis, which may favor 
NO
•
 production and protein SNO. Redox signaling triggers a protective kinase cascade including PKC and 
converging on mPTP. So that, mPTP closure may be dependent on ROS/RNS signaling effects, both 
upstream, together acidotic effect, and downstream, depending on kinase effects [47, 54].  
Therefore, mitochondria are involved at least in four different steps to limit ROS generation and 
reperfusion injury, and to trigger kinase activation by ROS-signaling: 
1) in early reperfusion mitochondria are the targets of acidosis; thus preventing mPTP opening and 
avoiding RIRR; 
2) the activation of mKATP channels allows the formation of small amounts of ROS: mitochondria are 
triggers or signal amplifiers; 
3) mitochondria are targets of signaling pathways with translocation of several kinases on mitochondrial 
membranes as well as within the interspaces of membrane and the matrix; therefore they are end-
effectors of protection (in terms of inhibition of mPTP opening and of reduced release of pro-apoptotic 
factors into the cytosol);  
4) mitochondria are targets of damage and protection from it (in terms of their functional and 
morphological integrity). 
Points to be underlined:  
We should consider that mitochondria represent more than the 30% of the cardiomyocyte mass and ROS 
produced by RIRR in post-ischemic phase may be among the major cause of ROS generation.  
The mitochondrial components involved in damage and protection are several, including those seen 
above. Specifically in cardiac protection we may have the mitochondrial translocation of some elements 
of RISK pathway and/or STAT3 of SAFE pathway [78, 89, 164]. These enzymes will induce phosphorylation 
of several components of mitochondria including the putative elements of mPTP and mKATP channels 
which will preserve mitochondrial integrity and will mediate protection. On the contrary, in non-
protected hearts there is the intervention of death factors, such as PKCδ and Beclin-1, which may modify 
mitochondria function inducing all form of cell death [59, 112, 222]. In addition, in the reperfusion phase 
the abrupt recovery of pH, Ca
2+
 overload and the overwhelming presence of ROS may be responsible of 
mPTP formation and RIRR, which may induce redox stress. Interestingly, a lower threshold for triggering 
the mPTP opening in response to Ca
2+
 overload and an increased ROS generation has been associated to 
the higher susceptibility of late pregnant rodent hearts to I/R injury [120]. 
It is of note that, though PostC affects structural features of mitochondria, it does not influence 
mitochondrial respiration [154]. In particular, in mitochondria isolated from PostC hearts basal state 4 or 
ADP-stimulated state 3 respirations are not affected, thus excluding uncoupling or inhibition of the 
respiratory chain as a mechanism of mPTP inhibition [4]. Nevertheless, while basal respiration was not 
affected, ADP-stimulated respiration was increased after pharmacological PostC with morphine [145]. 
This last observation is in line with many reports showing that a mild degree of mitochondrial dysfunction 
confers protection against I/R injury [173]. It is also in line with the important role of mitochondrial Cx43 
for oxygen consumption and ATP production. In fact inhibition or reduction of mitochondrial Cx43 
specifically decreases complex I respiration [20]. Mitochondrial Cx43 is important for both ROS signaling 
and respiration in cardiac conditioning. 
It may seem paradoxical that post-ischemic mitochondrial dysfunction does not add injury, but confers 
protection. For several authors, including us, this is the basis of the concept that cardioprotection is 
afforded by a partial degree of mitochondrial dysfunction which may lead to ROS signaling [38, 162, 173]. 
In fact, when oxygen supply is re-established after a prolonged ischemia, if something (e.g., acidosis, 
Cyclosporin A) prevents prolonged mPTP opening and RIRR, the partial mitochondrial dysfunction may 
allow ROS signaling. 
Overall, whereas ischemia and reperfusion damage mitochondria (e.g., limited oxidative 
phosphorylation), mitochondria themselves may contribute to myocardial injury (e.g., mPTP opening-
induced cell death) and protection (e.g., limiting mPTP opening and allowing redox signaling). 
Cardioprotection may occur because of a favorable reaction between ROS and RNS, leading to reversible 
modifications of targets. This may trigger beneficial signaling in the appropriate microdomains, such as, 
for example, S-nitrosylation of membrane and organelle enzymes and channels. 
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Figure Legends 
 
Figure 1. Ischemia/reperfusion injury and pre- and post-conditioning effects. 
Ischemia/reperfusion injury is characterized by the development of contractile dysfunction, arrhythmias, 
and endothelial dysfunction. Pre- and post-conditioning (IP or PostC) cardioprotective effect results in a 
decrease of infarct size, of arrhythmias and an improvement of post-ischemic contractile function. 
Myocardial stunning (i.e. the transient mechanical dysfunction that persists after reperfusion despite 
restoration of normal coronary flow) may remain unaffected by ischemic conditioning [159, 234]. 
 
 
Figure 2. Proposed cardioprotection pathway triggered by preconditioning. 
Brief periods (a few minutes) of ischemia (black box) intervalled by brief periods of re-perfusion (white 
boxes) are used to precondition the myocardium against a sustained infarcting ischemia followed by 
reperfusion. Preconditioning cardioprotective pathway is divided in: a trigger phase, in which Ade 
(adenosine), BK (bradykinin), and other surface receptors lead to mKATP opening, mitochondrial ROS/RNS 
formation and PKC activation; an ischemic phase, in which PKC acts as a memory; a reperfusion phase, in 
which signal transduction pathways (RISK and SAFE) act to maintain mPTP in a closed state. Redox 
signaling and a low pH at the time of myocardial reperfusion are required to mediate the 
cardioprotection elicited by ischemic preconditioning. The diagram here presented is a simplification of 
the complex pathways activated by conditioning protocol. Moreover many links between the arrows 
need more evidences to be confirmed. 
Acronyms are reported in the text. 
  
Figure 3. Mitochondrial permeability transition pore (mPTP) opening state during ischemia and 
reperfusion. 
During ischemia the closed state of mPTP is maintained by intracellular acidosis (low pH) despite an 
increase of cellular levels of ROS, Ca
2+
 and inorganic phosphate (Pi), thus leading to limited cellular injury. 
During reperfusion mPTP opening is promoted by the recovery of pH towards normal values, elevated 
[Ca
2+
] and bad ROS formation due to RIRR. Prolonged opened state induces irreversible injury and leads 
to cell death. 
 
Figure 4. Oxidative modification of protein thiols.  
Under oxidative stress, protein cysteines are subject to either reversible or irreversible oxidative 
modification. Protein cysteine residues are important targets in ROS/RNS signaling depending on 
intracellular pH. Protein cysteine residues with the pKA lower than intracellular pH display more thiolate 
anion which can rapidly react with ROS/RNS. 
Reversible modifications: cysteine sulfenic acid, disulfide bond, S-nitrosylation, and S-glutathionylation 
formation play important roles in cellular redox regulation in the presence of other surrounding thiols 
(RSH), nitrogens (NHR) or GSH. When cellular reducing status returns to normal, cysteine modifications 
are reversed by antioxidant systems such as glutaredoxin (Grx) and Trx. 
Irreversible modifications: protein thiols are oxidized to sulfinic and sulfonic acid, leading to loss of 
protein function and protein degradation, which will not necessarily lead to cell damage. Among 
irreversible modifications is included protein tyrosine nitration. See also text for further explanation.  
 Figure 5. Proposed cardioprotection pathway triggered by postconditioning.  
Brief cycles (a few seconds) of ischemia/reperfusion (black and with boxes) immediately after a 
prolonged ischemia are used to condition the myocardium against ischemia/reperfusion injury. These 
maneuvers maintain acidosis in early reperfusion and allow the heart to activate cardioprotective signal 
pathway (RISK and SAFE), thus leading to mPTP closure and reduced ROS production. Redox signaling and 
a low pH at the time of intermittent reperfusion are required to mediate the cardioprotection elicited by 
ischemic postconditioning. The diagram here presented is a simplification of the complex pathways 
activated by conditioning protocol. Moreover many links between the arrows need more evidences to be 
confirmed. 
INN, inner membrane, OUT, outer membrane of mitochondria; other acronyms are reported in the text. 
 
Figure 6. ROS formation within and outside mitochondria 
O2
-·
 is mainly generated at complex I and III of the electron transport chain and dismutated to H2O2 by 
different isoforms of SOD: MnSOD in the matrix and CuZnSOD in the intermembrane space and cytosol. 
H2O2 is further detoxified to water by glutathione peroxidase (GPX), by catalase (CAT) and Trx2.  
While H2O2 easily cross the bilayer lipid membranes, the O2¯
·
 needs a pore of AC. The thickness of broken 
lines represents the easiness to diffuse through the membrane. O2¯
·
 and H2O2 can react (Haber-Weiss 
reaction) and form the most dangerous OH
·
. 
Superoxide anion can react with NO
•
 to generate ONOO
-
 and other RNS. The switch from redox signaling 
to redox stress does not depend only by the type of ROS/RNS but also on the amount of ROS/RNS and 
the vicinity of targets and antioxidants. INN, inner membrane, OUT, outer membrane of mitochondria; 
other acronyms are reported in the text. 
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